Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics filed an 8-K highlighting updated interim Phase 2 ADVANCED-2 data for its investigational cell-based therapy TARA-002 in high-risk non-muscle invasive bladder cancer. In the BCG-unresponsive cohort, TARA-002 achieved a high-grade complete response rate of 65.7% (23/35) at any time, 68.2% at six months and 33.3% at 12 months. In BCG-naïve patients, the high-grade complete response rate was 72.4% (21/29) at any time, 66.7% at six months and 57.9% at 12 months. Across 74 treated patients, most treatment-related adverse events were Grade 1 and transient, with no Grade 3 or higher treatment-related events, no related serious events and no discontinuations due to toxicity. Protara plans to complete enrollment of the registrational BCG-unresponsive cohort of ADVANCED-2 and to initiate the registrational ADVANCED-3 trial in BCG-naïve patients in the second half of 2026, while also advancing TARA-002 in pediatric lymphatic malformations and IV choline chloride for parenteral nutrition–dependent patients.
Janus Henderson Group plc reported beneficial ownership of 5,141,616 shares of Protara Therapeutics, Inc. common stock, representing 10.0% of the class as of 12/31/2025. All shares are held with shared voting and dispositive power.
The stake is attributed to multiple Janus Henderson asset management subsidiaries that exercise investment and voting discretion for their managed portfolios, which receive all dividends and sale proceeds. Janus Henderson certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protara Therapeutics.
Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.
The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.
Protara Therapeutics VP, Controller Hannah Fry reported a tax-related share withholding. On 01/26/2026, 1,457 shares of Protara Therapeutics common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 24, 2025. After this withholding, Fry beneficially owned 42,723 shares of Protara common stock in direct ownership.
Protara Therapeutics, Inc. Chief Financial Officer Patrick Fabbio reported an automatic share withholding related to equity compensation. On 01/26/2026, 3,261 shares of common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations arising from the vesting of a previously granted restricted stock unit award. After this tax withholding, Fabbio directly beneficially owns 64,115 shares of Protara common stock.
Protara Therapeutics CEO and President Jesse Shefferman, a director of Protara Therapeutics, Inc. (TARA), reported a routine share withholding related to equity compensation. On January 26, 2026, the company withheld 8,732 shares of common stock at $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award granted on January 24, 2025. After this tax withholding, Shefferman beneficially owns 1,021,832 shares of Protara common stock directly.
Protara Therapeutics reported an insider share withholding by its Chief Scientific Operations Officer, Jacqueline Zummo. On January 26, 2026, 3,724 shares of common stock were withheld at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award that was granted on January 24, 2025. After this tax-related transaction, Zummo beneficially owns 118,559 shares of Protara common stock directly.
Protara Therapeutics, Inc. CEO and President Jesse Shefferman reported a Form 4 transaction involving company common stock. On January 20, 2026, 16,322 shares of Protara Therapeutics common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations tied to previously granted restricted stock unit awards that vested. After this tax withholding, Shefferman beneficially owned 1,030,564 shares of Protara common stock directly.